<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00937521</url>
  </required_header>
  <id_info>
    <org_study_id>V72P16</org_study_id>
    <secondary_id>2009-010106-11</secondary_id>
    <nct_id>NCT00937521</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants</brief_title>
  <official_title>A Phase 2 Partially Observer-Blind Randomized Controlled Multicenter Dose-Ranging and Formulation-Finding Study of a New Novartis Meningococcal B Recombinant Vaccine Evaluating the Safety and Immunogenicity When Given Concomitantly With Routine Vaccines in 2-month-old Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is aimed at assessing the safety and immunogenicity of different doses and
      formulations of a new Novartis Meningococcal B Recombinant Vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages of Subjects With Serum Bactericidal Activity (hSBA) ≥ 1:5 at 1 Month After Third Vaccination</measure>
    <time_frame>At baseline (pre-vaccination) and 30 days after the third vaccination.</time_frame>
    <description>To assess the immunogenicity of seven different formulations of 4CMenB (groups I-VI and VIII) given to healthy infants at 2,3 and 4 months of age as measured by percentages of subjects with serum bactericidal activity (SBA) titer≥1:5 against 44/76-SL, 5/99 and NZ98/254 reference strains, at 1 month after the third vaccination.. The analysis was done on the Per Protocol Primary Population at one month after third injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Fever ≥ 38.5 °C (Rectal Temperature) Within 3 Days (Day 1-3) After First Vaccination</measure>
    <time_frame>Day 1 to day 3 after first vaccination.</time_frame>
    <description>To assess if any of six different formulations of vaccine groups (Group II to Group VI, Group VIII) reduced the incidence of fever &gt;=38.5C (rectal) occurring within three days (day 1-day3) following first vaccination. The analysis was done on the Safety Population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Bactericidal Titers (GMTs), One Month After Third and Booster Vaccination (Men B at 12 Months of Age)</measure>
    <time_frame>At baseline (pre-vaccination), 30 days after the third vaccination, at booster Baseline and at booster vaccination (12 months of age)</time_frame>
    <description>ToTo assess the immune response of seven different formulations of meningococcal multi-component recombinant, adsorbed vaccine (rMenB+OMV NZ or rMenB (no OMV)) in healthy toddlers as measured by SBA geometric mean titers (GMTs) at:
One month after third vaccination.
One month after booster vaccination (Men B at 12 months of age).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Bactericidal Titers,One Month After Primary and Booster Vaccination (Men B at 12 Months of Age)</measure>
    <time_frame>At Baseline (pre-vaccination), at 30 days after the third vaccination, at booster Baseline, at 30 days</time_frame>
    <description>To compare the antibody response of meningococcal multi-component recombinant, adsorbed vaccine (formulation I vs. formulation VIII) and of routine infant vaccine given with or without prophylactic administration of paracetamol medication in healthy toddlers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratios, One Month After Primary and Booster Vaccination (Men B at 12 Months of Age)</measure>
    <time_frame>After the third and the booster vaccination.</time_frame>
    <description>To compare the antibody response between meningococcal multi-component recombinant adsorbed vaccine (formulation I) and routine infant vaccine group along with meningococcal multi-component recombinant adsorbed vaccine with prophylactic administration of paracetamol medication as measured by Geometric Mean Ratios (GMRs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA≥1:5, Persistence of Bactericidal Antibodies at 12 Months of Age (Pre-fourth Dose)</measure>
    <time_frame>12 months (pre-fourth vaccination)</time_frame>
    <description>To assess the persistence of bactericidal antibodies at 12 months of age after primary vaccination - three doses of one of the seven different formulations of rMenB+OMV NZ or rMenB (no OMV) (Group I-VI and VIII) and rMenB+OMV NZ with paracetamol medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA≥1:5, Persistence of Bactericidal Antibodies at 12 Months of Age (One Month-post Fourth Dose)</measure>
    <time_frame>1 month after fourth vaccination</time_frame>
    <description>To assess if any of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (groups I-VI and VIII) induced sufficient immune response when given to healthy toddlers at 12 months of age, as measured by percentage of subjects with SBA titer ≥ 1:5, at 1 month after the fourth vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Bactericidal Titers, After Primary and Booster Vaccinations (Men B at 12 Months of Age)</measure>
    <time_frame>At 13 months</time_frame>
    <description>To assess the induction of immunological memory of three doses of meningococcal multi-component recombinant, adsorbed vaccine by comparing the serum bactericidal antibodies Geometric Mean Bactericidal Titers (GMTs) response in healthy toddlers administered the fourth dose at 12 months of age to the response in meningococcal B vaccine naive toddlers (Group VII) receiving the first dose of meningococcal multi-component recombinant, adsorbed vaccine at 12 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA ≥1:5, First Dose of Meningococcal B Vaccine (One Month After Booster)</measure>
    <time_frame>1 month after booster</time_frame>
    <description>To assess the immune response of first dose of meningococcal multi-component recombinant, adsorbed vaccine given at 12 months of age to toddlers who previously received three doses of MenC-CRM197 vaccine as infants (group VII).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Reactogenicity of Study Vaccines Within 7 Days After Second and Third Vaccination</measure>
    <time_frame>Day 1 through day 7 after second and third vaccination.</time_frame>
    <description>To assess if any of six different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (Group II to VI, Group VIII) reduced the incidence of fever ≥ 38.5ºC (rectal) occurring within 3 days (day 1-3) following second and third vaccination and 7 days (day 1-7) following each vaccination as compared to rMenB+OMV NZ (Group I).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local Reactions Within 7 Days (Day 1-7) After Each Vaccination</measure>
    <time_frame>Day 1 through day 7 after each vaccination.</time_frame>
    <description>To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting solicited local reactions within 7 days (day 1-7) after each vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Systemic Reactions Within 7 Days (Day 1-7) After Each Vaccination</measure>
    <time_frame>Day 1 through day 7 after each vaccination.</time_frame>
    <description>To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting solicited systemic reactions within 7 days (day 1-7) after each vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Unsolicited Adverse Events Within 7 Days (Day 1-7) After Each Vaccination</measure>
    <time_frame>Day 1 through day 7 after each vaccination.</time_frame>
    <description>To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting unsolicited Adverse Events (AEs), serious adverse events (SAEs), medically attended AEs, AEs leading to premature withdrawal (throughout the study period) within 7 days (day 1-7) after each vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Severe Adverse Events and Adverse Events Necessitating a Medical Office or Emergency Room (ER) Visit and/or Resulting in Premature Withdrawal of the Subject From the Study, Throughout the Study Period.</measure>
    <time_frame>Overall study period.</time_frame>
    <description>To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting Severe Adverse Events (SAEs) and Adverse Events (AEs) necessitating a medical office or Emergency Room (ER) visit and/or resulting in premature withdrawal of the subject from the study, throughout the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Local and Systemic Reactions Within 7 Days (Day 1-7) After Second rMenB+OMV NZ Vaccination in MenC Group</measure>
    <time_frame>Day 1 through day 7 at 13 months age.</time_frame>
    <description>To assess the safety and tolerability of two doses of rMenB+OMV NZ vaccine (Group VII) given at 12 and 13 months of age to toddlers who previously received three doses of Menjugate as infants.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">1507</enrollment>
  <condition>Meningococcal Meningitis</condition>
  <condition>Meningococcal Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vaccine candidate formulation I</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vaccine candidate formulation II</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vaccine candidate formulation III</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vaccine candidate formulation IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vaccine candidate formulation V</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vaccine candidate formulation VI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vaccine candidate formulation I with antipyretic</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal B vaccine</intervention_name>
    <description>Vaccine candidate formulation I</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal B vaccine</intervention_name>
    <description>Vaccine candidate formulation II</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal B vaccine</intervention_name>
    <description>Vaccine candidate formulation III</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal B vaccine</intervention_name>
    <description>Vaccine candidate formulation IV</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal B vaccine</intervention_name>
    <description>Vaccine candidate formulation V</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal B vaccine</intervention_name>
    <description>Vaccine candidate formulation VI</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Control</description>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal B vaccine with antipyretic</intervention_name>
    <description>Vaccine candidate formulation I with antipyretic</description>
    <arm_group_label>8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy 2-month old infants (55-89 days, inclusive), born after full term pregnancy,
             gestational age ≥ 37 weeks and a birth weight ≥ 2.5 kg

          -  Available for all the visits scheduled in the study and for whom a parent/legal
             guardian is willing/able to comply with all protocol requirements

        Exclusion Criteria:

          -  Any meningococcal B or C vaccine administration

          -  Prior vaccination with any Diphtheria, Tetanus, Pertussis (acellular or whole cell),
             Polio (either Inactivated or Oral), Haemophilus influenzae type b (Hib), and
             Pneumococcal antigens;

          -  Any ascertained or suspected disease caused by N. meningitidis

          -  Household contact with and/or intimate exposure to an individual with laboratory
             confirmed N. meningitidis

          -  History of severe allergic reaction after previous vaccinations

          -  Recent significant acute or chronic infection

          -  Oral or parenteral antibiotic treatment in the 7 days prior to the scheduled blood
             draw;

          -  Any serious chronic or progressive disease according to the judgment of the
             investigator (e.g., neoplasm, diabetes mellitus Type I, cardiac disease, hepatic
             disease, progressive neurological disease or seizure, either associated with fever or
             as part of an underlying neurological disorder or syndrome, autoimmune disease, HIV
             infection or AIDS, or blood dyscrasias or diathesis, signs of cardiac or renal failure
             or severe malnutrition)

          -  Any impairment/alteration of the immune system resulting from (for example):

               -  Receipt of any immunosuppressive therapy at any time since birth

               -  Receipt of immunostimulants at any time since birth

               -  Use of systemic corticosteroids or chronic use of inhaled high-potency
                  corticosteroids at any time since birth

          -  Receipt of blood, blood products and/or plasma derivatives or any parenteral
             immunoglobulin preparation

          -  Participation in another clinical trial

          -  Family members and household members of research staff

          -  History of seizure

          -  Any contraindication to paracetamol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Days</minimum_age>
    <maximum_age>89 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Privado de Córdoba CMC SA</name>
      <address>
        <city>Naciones Unidas 346</city>
        <state>Cordoba</state>
        <zip>X5016KHE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidad de Chile, Av Independencia 1027</name>
      <address>
        <city>Comuna de Independencia</city>
        <state>Santiago</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio Manuel Bustos</name>
      <address>
        <city>Lo Cruzat 486, Quilicura</city>
        <state>Santiago</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samostatna ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>O. Kubina 17</city>
        <state>Boskovice</state>
        <zip>680 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samostatna ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Neklez 3</city>
        <state>Brno</state>
        <zip>628 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samostatna ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Pernštýnská 127/l</city>
        <state>Chlumec nad Cidlinou</state>
        <zip>503 51</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zdravotní středisko</name>
      <address>
        <city>Vaclavska 4186</city>
        <state>Chomutov</state>
        <zip>430 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Decin, Detske oddělení</name>
      <address>
        <city>U nemocnice 1</city>
        <state>Děčín</state>
        <zip>405 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakulta vojenskeho zdravotnictvi UO</name>
      <address>
        <city>Trebešská 1575</city>
        <state>Hradec Králové</state>
        <zip>50001</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samostatna ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Masarykova 389</city>
        <state>Humpolec</state>
        <zip>396 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samostatna ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Ruských legii 352</city>
        <state>Jindřichův Hradec</state>
        <zip>377 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samostatna ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Hrnčířská 1401</city>
        <state>Lipník nad Bečvou</state>
        <zip>751 31</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oblastni nemocnice Nachod, Destske oddělení</name>
      <address>
        <city>Purkyňova 446</city>
        <state>Náchod</state>
        <zip>547 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samostatna ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>U lékárny 306</city>
        <state>Odolena Voda</state>
        <zip>250 70</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prakticky lekar pro deti a dorost</name>
      <address>
        <city>Dvouletky 54</city>
        <state>Ostrava</state>
        <zip>700 30</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KHS Ostrava, Protiepidemické oddělení</name>
      <address>
        <city>Na Bělidle 7</city>
        <state>Ostrava</state>
        <zip>702 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Pardubice, Destske odděleni</name>
      <address>
        <city>Kyjevská 44</city>
        <state>Pardubice</state>
        <zip>532 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Bory</name>
      <address>
        <city>E. Beneše 13</city>
        <state>Plzeň</state>
        <zip>305 99</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samostatna ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Chrudimska 2a</city>
        <state>Praha 3</state>
        <zip>130 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samostatna ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Kladenská 53</city>
        <state>Praha 6</state>
        <zip>160 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samostatna ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Velka Michalska 22</city>
        <state>Znojmo</state>
        <zip>669 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Házi Gyermekorvosi szolgálat</name>
      <address>
        <city>Honvéd u.2.</city>
        <state>Bordány</state>
        <zip>6795</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medszolg 2000 Bt, 6723, Szeged, Dandár u.4</name>
      <address>
        <city>Ányos u.4.</city>
        <state>Budapest</state>
        <zip>1031</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erzsébet Kórház Gyermekosztály</name>
      <address>
        <city>Hodmezovasarhely</city>
        <state>dr. Imre József u.2.</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baby Box Bt,, 6724, Szeged, Kossuth Lajos sgt.109</name>
      <address>
        <city>Szeged</city>
        <state>Kossuth Lajos sgt.109</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Bán Mariann és Társa Bt.</name>
      <address>
        <city>Kando Kalman u.1</city>
        <state>Miskolc</state>
        <zip>3534</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Futurnest Kft</name>
      <address>
        <city>Selyemrét u.1.</city>
        <state>Miskolc</state>
        <zip>3527</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ped-Med Kft. , 3434 Mályi, Fő u.12.</name>
      <address>
        <city>Fő u.12.</city>
        <state>Mályi</state>
        <zip>3434</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.K. Sipka és Kovács Eü. Bt.</name>
      <address>
        <city>Csongrádi sgt. 63.</city>
        <state>Szeged</state>
        <zip>6723</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oszila Kft. 6723, Szeged, Debreceni u.10-14.</name>
      <address>
        <city>Debreceni u.10-14.</city>
        <state>Szeged</state>
        <zip>6723</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Győriné dr. Bari Eszter egyéni vállalkozó</name>
      <address>
        <city>Csongrad</city>
        <state>Szentháromság tér 10</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vas Megyei Markusovszky Kórház, Gyermekosztály</name>
      <address>
        <city>Markusovszky u. 1-3</city>
        <state>Szombathely</state>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Neonatologia e Terapia Intensiva Neonatale, &quot;Ospedale dei Bambini&quot;, Presidio Ospedaliero dell'Azienda Ospedaliera Spedali Civili di Brescia</name>
      <address>
        <city>P.le Spedali di Brescia,1</city>
        <state>Brescia</state>
        <zip>25125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Pediatria dell'Università degli Studi di Firenze</name>
      <address>
        <city>Viale Pieraccini n. 24</city>
        <state>Firenze</state>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Messina, Pad. NI - A.O.U. Policlinico G.Martino</name>
      <address>
        <city>Via Consolare Valeria, 1</city>
        <state>Messina</state>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS dell'Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena di Milano</name>
      <address>
        <city>Via Commenda, 9</city>
        <state>Milano</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatria dell'Ospedale Sacco di Milano</name>
      <address>
        <city>Via G.B.Grossi 74</city>
        <state>Milano</state>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Pediatria Azienda Ospedaliera di Padova</name>
      <address>
        <city>Via Giustiniani, 3</city>
        <state>Padova</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2009</study_first_submitted>
  <study_first_submitted_qc>July 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2009</study_first_posted>
  <results_first_submitted>February 13, 2015</results_first_submitted>
  <results_first_submitted_qc>February 13, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 4, 2015</results_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunogenicity</keyword>
  <keyword>Meningitis</keyword>
  <keyword>Antibody</keyword>
  <keyword>Infants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antipyretics</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>B+OMV (Group I)</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation I) and routine vaccines at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
        </group>
        <group group_id="P2">
          <title>B+½ OMV (Group II)</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation II) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
        </group>
        <group group_id="P3">
          <title>B+1/4 OMV (Group III)</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation III) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
        </group>
        <group group_id="P4">
          <title>B (Group IV)</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation IV) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
        </group>
        <group group_id="P5">
          <title>½ (B+OMV) (Group V)</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation V) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
        </group>
        <group group_id="P6">
          <title>PH2 B+OMV (Group VI)</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation VI) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
        </group>
        <group group_id="P7">
          <title>MenC (Group VII)</title>
          <description>Subjects received one dose of meningococcal C conjugate vaccine (Menjugate®; Men C) and routine vaccine at 2,3,4 months of age, one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation VII) and routine vaccine at 12 months of age, one dose of rMenB+OMV NZ and one dose of MenC at 13 months of age.</description>
        </group>
        <group group_id="P8">
          <title>Par+B+OMV (Group VIII)</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation I) with paracetamol and routine vaccines at 2,3,4,12 months of age and MenCCRM197 at 13 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study - Prior to Booster Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="190"/>
                <participants group_id="P3" count="192"/>
                <participants group_id="P4" count="188"/>
                <participants group_id="P5" count="191"/>
                <participants group_id="P6" count="188"/>
                <participants group_id="P7" count="186"/>
                <participants group_id="P8" count="184"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Premature Withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="185"/>
                <participants group_id="P2" count="185"/>
                <participants group_id="P3" count="186"/>
                <participants group_id="P4" count="187"/>
                <participants group_id="P5" count="188"/>
                <participants group_id="P6" count="187"/>
                <participants group_id="P7" count="181"/>
                <participants group_id="P8" count="183"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate enrollment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Booster Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="163"/>
                <participants group_id="P3" count="169"/>
                <participants group_id="P4" count="170"/>
                <participants group_id="P5" count="168"/>
                <participants group_id="P6" count="165"/>
                <participants group_id="P7" count="165"/>
                <participants group_id="P8" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Premature Withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="161"/>
                <participants group_id="P3" count="164"/>
                <participants group_id="P4" count="167"/>
                <participants group_id="P5" count="163"/>
                <participants group_id="P6" count="160"/>
                <participants group_id="P7" count="160"/>
                <participants group_id="P8" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>B+OMV (Group I)</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation I) and routine vaccines at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
        </group>
        <group group_id="B2">
          <title>B+½ OMV (Group II)</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation II) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
        </group>
        <group group_id="B3">
          <title>B+1/4 OMV (Group III)</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation III) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
        </group>
        <group group_id="B4">
          <title>B (Group IV)</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation IV) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
        </group>
        <group group_id="B5">
          <title>½ (B+OMV) (Group V)</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation V) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
        </group>
        <group group_id="B6">
          <title>PH2 B+OMV (Group VI)</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation VI) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
        </group>
        <group group_id="B7">
          <title>MenC (Group VII)</title>
          <description>Subjects received one dose of meningococcal C conjugate vaccine (Menjugate®; Men C) and routine vaccine at 2,3,4 months of age, one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation VII) and routine vaccine at 12 months of age, one dose of rMenB+OMV NZ and one dose of MenC at 13 months of age.</description>
        </group>
        <group group_id="B8">
          <title>Par+B+OMV (Group VIII)</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation I) with paracetamol and routine vaccines at 2,3,4,12 months of age and MenCCRM197 at 13 months of age.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="188"/>
            <count group_id="B2" value="190"/>
            <count group_id="B3" value="192"/>
            <count group_id="B4" value="188"/>
            <count group_id="B5" value="191"/>
            <count group_id="B6" value="188"/>
            <count group_id="B7" value="186"/>
            <count group_id="B8" value="184"/>
            <count group_id="B9" value="1507"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                    <measurement group_id="B2" value="190"/>
                    <measurement group_id="B3" value="192"/>
                    <measurement group_id="B4" value="188"/>
                    <measurement group_id="B5" value="191"/>
                    <measurement group_id="B6" value="188"/>
                    <measurement group_id="B7" value="186"/>
                    <measurement group_id="B8" value="184"/>
                    <measurement group_id="B9" value="1507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="96"/>
                    <measurement group_id="B5" value="79"/>
                    <measurement group_id="B6" value="93"/>
                    <measurement group_id="B7" value="98"/>
                    <measurement group_id="B8" value="72"/>
                    <measurement group_id="B9" value="699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="110"/>
                    <measurement group_id="B4" value="92"/>
                    <measurement group_id="B5" value="112"/>
                    <measurement group_id="B6" value="95"/>
                    <measurement group_id="B7" value="88"/>
                    <measurement group_id="B8" value="112"/>
                    <measurement group_id="B9" value="808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With Serum Bactericidal Activity (hSBA) ≥ 1:5 at 1 Month After Third Vaccination</title>
        <description>To assess the immunogenicity of seven different formulations of 4CMenB (groups I-VI and VIII) given to healthy infants at 2,3 and 4 months of age as measured by percentages of subjects with serum bactericidal activity (SBA) titer≥1:5 against 44/76-SL, 5/99 and NZ98/254 reference strains, at 1 month after the third vaccination.. The analysis was done on the Per Protocol Primary Population at one month after third injection.</description>
        <time_frame>At baseline (pre-vaccination) and 30 days after the third vaccination.</time_frame>
        <population>Analysis as per PP population.</population>
        <group_list>
          <group group_id="O1">
            <title>B+OMV (Group I)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation I) and routine vaccines at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B+½ OMV (Group II)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation II) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B+1/4 OMV (Group III)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation III) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O4">
            <title>B (Group IV)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation IV) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O5">
            <title>½ (B+OMV) (Group V)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation V) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O6">
            <title>PH2 B+OMV (Group VI)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation VI) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O7">
            <title>MenC (Group VII)</title>
            <description>Subjects received one dose of meningococcal C conjugate vaccine (Menjugate®; Men C) and routine vaccine at 2,3,4 months of age, one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation VII) and routine vaccine at 12 months of age, one dose of rMenB+OMV NZ and one dose of MenC at 13 months of age.</description>
          </group>
          <group group_id="O8">
            <title>Par+B+OMV (Group VIII)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation I) with paracetamol and routine vaccines at 2,3,4,12 months of age and MenCCRM197 at 13 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Serum Bactericidal Activity (hSBA) ≥ 1:5 at 1 Month After Third Vaccination</title>
          <description>To assess the immunogenicity of seven different formulations of 4CMenB (groups I-VI and VIII) given to healthy infants at 2,3 and 4 months of age as measured by percentages of subjects with serum bactericidal activity (SBA) titer≥1:5 against 44/76-SL, 5/99 and NZ98/254 reference strains, at 1 month after the third vaccination.. The analysis was done on the Per Protocol Primary Population at one month after third injection.</description>
          <population>Analysis as per PP population.</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="171"/>
                <count group_id="O4" value="174"/>
                <count group_id="O5" value="172"/>
                <count group_id="O6" value="173"/>
                <count group_id="O7" value="171"/>
                <count group_id="O8" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>44/76SLBaseline(N=166,171,168,170,169,168,168,166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="2" upper_limit="9"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O3" value="4" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O4" value="4" lower_limit="2" upper_limit="8"/>
                    <measurement group_id="O5" value="4" lower_limit="2" upper_limit="8"/>
                    <measurement group_id="O6" value="4" lower_limit="2" upper_limit="8"/>
                    <measurement group_id="O7" value="2" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O8" value="3" lower_limit="1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>44/76-SL &gt; 3rd(N=170,170,166,166,169,167,165,167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O3" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O5" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O6" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O7" value="6" lower_limit="3" upper_limit="11"/>
                    <measurement group_id="O8" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99-Baseline (N=162,162,161,161,166,166,161,157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="2" upper_limit="9"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="O3" value="6" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O4" value="4" lower_limit="2" upper_limit="9"/>
                    <measurement group_id="O5" value="8" lower_limit="5" upper_limit="14"/>
                    <measurement group_id="O6" value="4" lower_limit="2" upper_limit="8"/>
                    <measurement group_id="O7" value="6" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O8" value="4" lower_limit="1" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 &gt; 3rd (N=165,167,161,166,165,161,159,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O3" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O6" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O7" value="3" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="O8" value="99" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254Baseline(N=170,174,171,174,171,173,171,169</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.015" upper_limit="3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="1" lower_limit="0.015" upper_limit="3"/>
                    <measurement group_id="O4" value="1" lower_limit="0.015" upper_limit="3"/>
                    <measurement group_id="O5" value="1" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O6" value="1" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O7" value="2" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O8" value="1" lower_limit="0.015" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 &gt; 3rd (N=171,172,169,168,172,169,168,168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="71" upper_limit="84"/>
                    <measurement group_id="O2" value="67" lower_limit="59" upper_limit="74"/>
                    <measurement group_id="O3" value="56" lower_limit="48" upper_limit="64"/>
                    <measurement group_id="O4" value="1" lower_limit="0.015" upper_limit="3"/>
                    <measurement group_id="O5" value="62" lower_limit="54" upper_limit="69"/>
                    <measurement group_id="O6" value="81" lower_limit="74" upper_limit="87"/>
                    <measurement group_id="O7" value="2" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O8" value="74" lower_limit="67" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Bactericidal Titers (GMTs), One Month After Third and Booster Vaccination (Men B at 12 Months of Age)</title>
        <description>ToTo assess the immune response of seven different formulations of meningococcal multi-component recombinant, adsorbed vaccine (rMenB+OMV NZ or rMenB (no OMV)) in healthy toddlers as measured by SBA geometric mean titers (GMTs) at:
One month after third vaccination.
One month after booster vaccination (Men B at 12 months of age).</description>
        <time_frame>At baseline (pre-vaccination), 30 days after the third vaccination, at booster Baseline and at booster vaccination (12 months of age)</time_frame>
        <population>Per Protocol Primary and Booster populations.</population>
        <group_list>
          <group group_id="O1">
            <title>B+OMV (Group I)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation I) and routine vaccines at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B+½ OMV (Group II)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation II) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B+1/4 OMV (Group III)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation III) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O4">
            <title>B (Group IV)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation IV) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O5">
            <title>½ (B+OMV) (Group V)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation V) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O6">
            <title>PH2 B+OMV (Group VI)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation VI) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O7">
            <title>MenC (Group VII)</title>
            <description>Subjects received one dose of meningococcal C conjugate vaccine (Menjugate®; Men C) and routine vaccine at 2,3,4 months of age, one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation VII) and routine vaccine at 12 months of age, one dose of rMenB+OMV NZ and one dose of MenC at 13 months of age.</description>
          </group>
          <group group_id="O8">
            <title>Par+B+OMV (Group VIII)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation I) with paracetamol and routine vaccines at 2,3,4,12 months of age and MenCCRM197 at 13 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Bactericidal Titers (GMTs), One Month After Third and Booster Vaccination (Men B at 12 Months of Age)</title>
          <description>ToTo assess the immune response of seven different formulations of meningococcal multi-component recombinant, adsorbed vaccine (rMenB+OMV NZ or rMenB (no OMV)) in healthy toddlers as measured by SBA geometric mean titers (GMTs) at:
One month after third vaccination.
One month after booster vaccination (Men B at 12 months of age).</description>
          <population>Per Protocol Primary and Booster populations.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="171"/>
                <count group_id="O4" value="174"/>
                <count group_id="O5" value="172"/>
                <count group_id="O6" value="173"/>
                <count group_id="O7" value="171"/>
                <count group_id="O8" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>44/76-SL Base(N=166,171,168,170,169,168,168,166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="1.14" upper_limit="1.37"/>
                    <measurement group_id="O2" value="1.12" lower_limit="1.03" upper_limit="1.23"/>
                    <measurement group_id="O3" value="1.2" lower_limit="1.1" upper_limit="1.32"/>
                    <measurement group_id="O4" value="1.19" lower_limit="1.08" upper_limit="1.3"/>
                    <measurement group_id="O5" value="1.31" lower_limit="1.19" upper_limit="1.43"/>
                    <measurement group_id="O6" value="1.2" lower_limit="1.09" upper_limit="1.31"/>
                    <measurement group_id="O7" value="1.16" lower_limit="1.09" upper_limit="1.25"/>
                    <measurement group_id="O8" value="1.18" lower_limit="1.08" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>44/76-SL &gt; 3(N=170,170,166,166,169,167,165,167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101" lower_limit="90" upper_limit="113"/>
                    <measurement group_id="O2" value="112" lower_limit="101" upper_limit="126"/>
                    <measurement group_id="O3" value="113" lower_limit="101" upper_limit="126"/>
                    <measurement group_id="O4" value="62" lower_limit="56" upper_limit="70"/>
                    <measurement group_id="O5" value="71" lower_limit="64" upper_limit="80"/>
                    <measurement group_id="O6" value="102" lower_limit="92" upper_limit="114"/>
                    <measurement group_id="O7" value="1.24" lower_limit="1.11" upper_limit="1.39"/>
                    <measurement group_id="O8" value="102" lower_limit="91" upper_limit="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>44/76-SL – Base Boost(N=69,78,74,78,71,71,74,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.94" lower_limit="3.76" upper_limit="6.5"/>
                    <measurement group_id="O2" value="5.22" lower_limit="4.03" upper_limit="6.76"/>
                    <measurement group_id="O3" value="5.72" lower_limit="4.41" upper_limit="7.42"/>
                    <measurement group_id="O4" value="5.44" lower_limit="4.19" upper_limit="7.06"/>
                    <measurement group_id="O5" value="3.96" lower_limit="3.02" upper_limit="5.18"/>
                    <measurement group_id="O6" value="3.76" lower_limit="2.87" upper_limit="4.94"/>
                    <measurement group_id="O7" value="1.15" lower_limit="1.03" upper_limit="1.29"/>
                    <measurement group_id="O8" value="4.51" lower_limit="3.43" upper_limit="5.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>44/76-SL &gt; Boost(N=65,73,70,75,76,71,75,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" lower_limit="95" upper_limit="150"/>
                    <measurement group_id="O2" value="152" lower_limit="122" upper_limit="189"/>
                    <measurement group_id="O3" value="118" lower_limit="95" upper_limit="146"/>
                    <measurement group_id="O4" value="53" lower_limit="43" upper_limit="66"/>
                    <measurement group_id="O5" value="99" lower_limit="79" upper_limit="122"/>
                    <measurement group_id="O6" value="105" lower_limit="84" upper_limit="131"/>
                    <measurement group_id="O7" value="12" lower_limit="10" upper_limit="16"/>
                    <measurement group_id="O8" value="136" lower_limit="107" upper_limit="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99-Baseline-(N=162,162,161,161,166,166,161,157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" lower_limit="1.07" upper_limit="1.3"/>
                    <measurement group_id="O2" value="1.09" lower_limit="0.99" upper_limit="1.2"/>
                    <measurement group_id="O3" value="1.12" lower_limit="1.02" upper_limit="1.23"/>
                    <measurement group_id="O4" value="1.13" lower_limit="1.03" upper_limit="1.25"/>
                    <measurement group_id="O5" value="1.3" lower_limit="1.18" upper_limit="1.43"/>
                    <measurement group_id="O6" value="1.16" lower_limit="1.05" upper_limit="1.27"/>
                    <measurement group_id="O7" value="1.21" lower_limit="1.09" upper_limit="1.34"/>
                    <measurement group_id="O8" value="1.07" lower_limit="0.97" upper_limit="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 &gt; 3 (N=165,167,161,166,165,161,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="396" lower_limit="348" upper_limit="450"/>
                    <measurement group_id="O2" value="503" lower_limit="442" upper_limit="572"/>
                    <measurement group_id="O3" value="534" lower_limit="469" upper_limit="608"/>
                    <measurement group_id="O4" value="389" lower_limit="342" upper_limit="443"/>
                    <measurement group_id="O5" value="316" lower_limit="278" upper_limit="360"/>
                    <measurement group_id="O6" value="371" lower_limit="326" upper_limit="422"/>
                    <measurement group_id="O7" value="1.15" lower_limit="1.03" upper_limit="1.29"/>
                    <measurement group_id="O8" value="455" lower_limit="399" upper_limit="519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 Base Boost(N=71,76,80,72,77,78,70,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="53" upper_limit="88"/>
                    <measurement group_id="O2" value="91" lower_limit="71" upper_limit="116"/>
                    <measurement group_id="O3" value="111" lower_limit="87" upper_limit="141"/>
                    <measurement group_id="O4" value="74" lower_limit="57" upper_limit="94"/>
                    <measurement group_id="O5" value="54" lower_limit="42" upper_limit="68"/>
                    <measurement group_id="O6" value="64" lower_limit="50" upper_limit="81"/>
                    <measurement group_id="O7" value="1.11" lower_limit="0.95" upper_limit="1.29"/>
                    <measurement group_id="O8" value="106" lower_limit="82" upper_limit="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 &gt; Boost(N=73,77,79,72,76,74,69,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1950" lower_limit="1573" upper_limit="2417"/>
                    <measurement group_id="O2" value="1819" lower_limit="1478" upper_limit="2238"/>
                    <measurement group_id="O3" value="2238" lower_limit="1820" upper_limit="2751"/>
                    <measurement group_id="O4" value="730" lower_limit="590" upper_limit="903"/>
                    <measurement group_id="O5" value="983" lower_limit="801" upper_limit="1205"/>
                    <measurement group_id="O6" value="1321" lower_limit="1074" upper_limit="1624"/>
                    <measurement group_id="O7" value="41" lower_limit="29" upper_limit="57"/>
                    <measurement group_id="O8" value="2182" lower_limit="1769" upper_limit="2691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254-BaselineN=170,174,171,174,171,173,171,169</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" lower_limit="0.99" upper_limit="1.06"/>
                    <measurement group_id="O2" value="1.02" lower_limit="0.99" upper_limit="1.05"/>
                    <measurement group_id="O3" value="1.03" lower_limit="1" upper_limit="1.06"/>
                    <measurement group_id="O4" value="1.04" lower_limit="1" upper_limit="1.07"/>
                    <measurement group_id="O5" value="1.03" lower_limit="1" upper_limit="1.06"/>
                    <measurement group_id="O6" value="1.04" lower_limit="1.01" upper_limit="1.08"/>
                    <measurement group_id="O7" value="1.06" lower_limit="1" upper_limit="1.13"/>
                    <measurement group_id="O8" value="1.02" lower_limit="0.99" upper_limit="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1month after 3rd vaccN=171,172,169,172,169,169,168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="8.59" upper_limit="12"/>
                    <measurement group_id="O2" value="7.81" lower_limit="6.69" upper_limit="9.12"/>
                    <measurement group_id="O3" value="5.74" lower_limit="4.92" upper_limit="6.71"/>
                    <measurement group_id="O4" value="1.05" lower_limit="0.9" upper_limit="1.23"/>
                    <measurement group_id="O5" value="6.66" lower_limit="5.71" upper_limit="7.77"/>
                    <measurement group_id="O6" value="11" lower_limit="9.16" upper_limit="13"/>
                    <measurement group_id="O7" value="1.05" lower_limit="1.01" upper_limit="1.1"/>
                    <measurement group_id="O8" value="8.48" lower_limit="7.24" upper_limit="9.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 Bas Bst N=141,155,155,150,150,153,148,143</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.43" upper_limit="1.8"/>
                    <measurement group_id="O2" value="1.28" lower_limit="1.15" upper_limit="1.43"/>
                    <measurement group_id="O3" value="1.23" lower_limit="1.1" upper_limit="1.37"/>
                    <measurement group_id="O4" value="1.11" lower_limit="0.99" upper_limit="1.24"/>
                    <measurement group_id="O5" value="1.35" lower_limit="1.21" upper_limit="1.5"/>
                    <measurement group_id="O6" value="1.41" lower_limit="1.26" upper_limit="1.57"/>
                    <measurement group_id="O7" value="1.03" lower_limit="1" upper_limit="1.06"/>
                    <measurement group_id="O8" value="1.48" lower_limit="1.32" upper_limit="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1month after boosterN=138,152,150,149,152,146,140</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="16" upper_limit="24"/>
                    <measurement group_id="O2" value="18" lower_limit="15" upper_limit="22"/>
                    <measurement group_id="O3" value="11" lower_limit="9.07" upper_limit="13"/>
                    <measurement group_id="O4" value="1.67" lower_limit="1.38" upper_limit="2.03"/>
                    <measurement group_id="O5" value="14" lower_limit="12" upper_limit="17"/>
                    <measurement group_id="O6" value="20" lower_limit="16" upper_limit="24"/>
                    <measurement group_id="O7" value="2.2" lower_limit="1.89" upper_limit="2.57"/>
                    <measurement group_id="O8" value="20" lower_limit="17" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Bactericidal Titers,One Month After Primary and Booster Vaccination (Men B at 12 Months of Age)</title>
        <description>To compare the antibody response of meningococcal multi-component recombinant, adsorbed vaccine (formulation I vs. formulation VIII) and of routine infant vaccine given with or without prophylactic administration of paracetamol medication in healthy toddlers.</description>
        <time_frame>At Baseline (pre-vaccination), at 30 days after the third vaccination, at booster Baseline, at 30 days</time_frame>
        <population>As per PP population.</population>
        <group_list>
          <group group_id="O1">
            <title>B+OMV (Group I)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation I) and routine vaccines at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Par+B+OMV (Group VIII)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation I) with paracetamol and routine vaccines at 2,3,4,12 months of age and MenCCRM197 at 13 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Bactericidal Titers,One Month After Primary and Booster Vaccination (Men B at 12 Months of Age)</title>
          <description>To compare the antibody response of meningococcal multi-component recombinant, adsorbed vaccine (formulation I vs. formulation VIII) and of routine infant vaccine given with or without prophylactic administration of paracetamol medication in healthy toddlers.</description>
          <population>As per PP population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>44/76-SL Strain - Baseline (N=166,166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="1.14" upper_limit="1.37"/>
                    <measurement group_id="O2" value="1.18" lower_limit="1.08" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>44/76-SL &gt; 3rd (N=170,167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101" lower_limit="90" upper_limit="113"/>
                    <measurement group_id="O2" value="102" lower_limit="91" upper_limit="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>44/76-SL Baseline booster (N=69,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.94" lower_limit="3.76" upper_limit="6.5"/>
                    <measurement group_id="O2" value="4.51" lower_limit="3.43" upper_limit="5.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>44/76-SL &gt; booster (N=65,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" lower_limit="95" upper_limit="150"/>
                    <measurement group_id="O2" value="136" lower_limit="107" upper_limit="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 Strain - Baseline (N=162,157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" lower_limit="1.07" upper_limit="1.3"/>
                    <measurement group_id="O2" value="1.07" lower_limit="0.97" upper_limit="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 &gt; 3rd (N=165,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="396" lower_limit="348" upper_limit="450"/>
                    <measurement group_id="O2" value="455" lower_limit="399" upper_limit="519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 Baseline booster (N=71,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="53" upper_limit="88"/>
                    <measurement group_id="O2" value="106" lower_limit="82" upper_limit="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 &gt; booser (N=73,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1950" lower_limit="1573" upper_limit="2417"/>
                    <measurement group_id="O2" value="2182" lower_limit="1769" upper_limit="2691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 Strain-Baseline (N=170,169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" lower_limit="0.99" upper_limit="1.06"/>
                    <measurement group_id="O2" value="1.02" lower_limit="0.99" upper_limit="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 &gt; 3rd (N=171,168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="8.59" upper_limit="12"/>
                    <measurement group_id="O2" value="8.48" lower_limit="7.24" upper_limit="9.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 Baseline booster (N=141,143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.43" upper_limit="1.8"/>
                    <measurement group_id="O2" value="1.48" lower_limit="1.32" upper_limit="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 &gt; booster (N= 138, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="16" upper_limit="24"/>
                    <measurement group_id="O2" value="20" lower_limit="17" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratios, One Month After Primary and Booster Vaccination (Men B at 12 Months of Age)</title>
        <description>To compare the antibody response between meningococcal multi-component recombinant adsorbed vaccine (formulation I) and routine infant vaccine group along with meningococcal multi-component recombinant adsorbed vaccine with prophylactic administration of paracetamol medication as measured by Geometric Mean Ratios (GMRs).</description>
        <time_frame>After the third and the booster vaccination.</time_frame>
        <population>As per PP population.</population>
        <group_list>
          <group group_id="O1">
            <title>B+OMV (Group I)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation I) and routine vaccines at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Par+B+OMV (Group VIII)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation I) with paracetamol and routine vaccines at 2,3,4,12 months of age and MenCCRM197 at 13 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratios, One Month After Primary and Booster Vaccination (Men B at 12 Months of Age)</title>
          <description>To compare the antibody response between meningococcal multi-component recombinant adsorbed vaccine (formulation I) and routine infant vaccine group along with meningococcal multi-component recombinant adsorbed vaccine with prophylactic administration of paracetamol medication as measured by Geometric Mean Ratios (GMRs).</description>
          <population>As per PP population.</population>
          <units>Ratios</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>44/76-SL &gt; 3rd (N=157,157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="69" upper_limit="93"/>
                    <measurement group_id="O2" value="84" lower_limit="72" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>44/76-SL &gt; Booster (N=59,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="18" upper_limit="31"/>
                    <measurement group_id="O2" value="28" lower_limit="21" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 &gt; 3rd (N=152,142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="345" lower_limit="292" upper_limit="408"/>
                    <measurement group_id="O2" value="417" lower_limit="350" upper_limit="497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 &gt; Booster (N=68,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="21" upper_limit="35"/>
                    <measurement group_id="O2" value="20" lower_limit="16" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 &gt; 3rd (N=162,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.65" lower_limit="8.19" upper_limit="11"/>
                    <measurement group_id="O2" value="8.69" lower_limit="7.36" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 &gt; Booster (N=129,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="10" upper_limit="15"/>
                    <measurement group_id="O2" value="14" lower_limit="11" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA≥1:5, Persistence of Bactericidal Antibodies at 12 Months of Age (Pre-fourth Dose)</title>
        <description>To assess the persistence of bactericidal antibodies at 12 months of age after primary vaccination - three doses of one of the seven different formulations of rMenB+OMV NZ or rMenB (no OMV) (Group I-VI and VIII) and rMenB+OMV NZ with paracetamol medication.</description>
        <time_frame>12 months (pre-fourth vaccination)</time_frame>
        <population>The analysis was done on the Per Protocol Booster population.</population>
        <group_list>
          <group group_id="O1">
            <title>B+OMV (Group I)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation I) and routine vaccines at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age..</description>
          </group>
          <group group_id="O2">
            <title>B+½ OMV (Group II)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation II) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B+1/4 OMV (Group III)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation III) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O4">
            <title>B (Group IV)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation IV) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age..</description>
          </group>
          <group group_id="O5">
            <title>½ (B+OMV) (Group V)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation V) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O6">
            <title>PH2 B+OMV (Group VI)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation VI) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O7">
            <title>MenC (Group VII)</title>
            <description>Subjects received one dose of meningococcal C conjugate vaccine (Menjugate®; Men C) and routine vaccine at 2,3,4 months of age, one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation VII) and routine vaccine at 12 months of age, one dose of rMenB+OMV NZ and one dose of MenC at 13 months of age.</description>
          </group>
          <group group_id="O8">
            <title>Par+B+OMV (Group VIII)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation I) with paracetamol and routine vaccines at 2,3,4,12 months of age and MenCCRM197 at 13 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA≥1:5, Persistence of Bactericidal Antibodies at 12 Months of Age (Pre-fourth Dose)</title>
          <description>To assess the persistence of bactericidal antibodies at 12 months of age after primary vaccination - three doses of one of the seven different formulations of rMenB+OMV NZ or rMenB (no OMV) (Group I-VI and VIII) and rMenB+OMV NZ with paracetamol medication.</description>
          <population>The analysis was done on the Per Protocol Booster population.</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="155"/>
                <count group_id="O3" value="155"/>
                <count group_id="O4" value="150"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="153"/>
                <count group_id="O7" value="148"/>
                <count group_id="O8" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>44/76-SL Pre-Boost(N=69,78,74,78,71,71,74,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="43" upper_limit="67"/>
                    <measurement group_id="O2" value="58" lower_limit="46" upper_limit="69"/>
                    <measurement group_id="O3" value="66" lower_limit="54" upper_limit="77"/>
                    <measurement group_id="O4" value="63" lower_limit="51" upper_limit="74"/>
                    <measurement group_id="O5" value="45" lower_limit="33" upper_limit="57"/>
                    <measurement group_id="O6" value="44" lower_limit="32" upper_limit="56"/>
                    <measurement group_id="O7" value="4" lower_limit="1" upper_limit="11"/>
                    <measurement group_id="O8" value="47" lower_limit="35" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 Pre-Boost(N=71,76,80,72,77,78,70,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O4" value="97" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O5" value="97" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O6" value="99" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O7" value="1" lower_limit="0.036" upper_limit="8"/>
                    <measurement group_id="O8" value="100" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 Pre-B(N=141,155,155,150,150,153,148,143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="7" upper_limit="19"/>
                    <measurement group_id="O2" value="6" lower_limit="3" upper_limit="11"/>
                    <measurement group_id="O3" value="5" lower_limit="2" upper_limit="10"/>
                    <measurement group_id="O4" value="3" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="O5" value="7" lower_limit="3" upper_limit="12"/>
                    <measurement group_id="O6" value="8" lower_limit="4" upper_limit="13"/>
                    <measurement group_id="O7" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O8" value="11" lower_limit="7" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA≥1:5, Persistence of Bactericidal Antibodies at 12 Months of Age (One Month-post Fourth Dose)</title>
        <description>To assess if any of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (groups I-VI and VIII) induced sufficient immune response when given to healthy toddlers at 12 months of age, as measured by percentage of subjects with SBA titer ≥ 1:5, at 1 month after the fourth vaccination.</description>
        <time_frame>1 month after fourth vaccination</time_frame>
        <population>The analysis was done on the Per Protocol Booster population.</population>
        <group_list>
          <group group_id="O1">
            <title>B+OMV (Group I)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation I) and routine vaccines at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B+½ OMV (Group II)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation II) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B+1/4 OMV (Group III)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation III) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O4">
            <title>B (Group IV)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation IV) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O5">
            <title>½ (B+OMV) (Group V)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation V) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O6">
            <title>PH2 B+OMV (Group VI)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation VI) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O7">
            <title>MenC (Group VII)</title>
            <description>Subjects received one dose of meningococcal C conjugate vaccine (Menjugate®; Men C) and routine vaccine at 2,3,4 months of age, one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation VII) and routine vaccine at 12 months of age, one dose of rMenB+OMV NZ and one dose of MenC at 13 months of age.</description>
          </group>
          <group group_id="O8">
            <title>Par+B+OMV (Group VIII)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation I) with paracetamol and routine vaccines at 2,3,4,12 months of age and MenCCRM197 at 13 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA≥1:5, Persistence of Bactericidal Antibodies at 12 Months of Age (One Month-post Fourth Dose)</title>
          <description>To assess if any of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (groups I-VI and VIII) induced sufficient immune response when given to healthy toddlers at 12 months of age, as measured by percentage of subjects with SBA titer ≥ 1:5, at 1 month after the fourth vaccination.</description>
          <population>The analysis was done on the Per Protocol Booster population.</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="149"/>
                <count group_id="O5" value="152"/>
                <count group_id="O6" value="146"/>
                <count group_id="O7" value="147"/>
                <count group_id="O8" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>44/76-SL &gt; Booster(N=65,73,70,75,76,71,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O4" value="97" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O6" value="99" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O7" value="84" lower_limit="74" upper_limit="91"/>
                    <measurement group_id="O8" value="100" lower_limit="94" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 strain (N=73,77,79,72,76,74,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O6" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O7" value="93" lower_limit="84" upper_limit="98"/>
                    <measurement group_id="O8" value="100" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (N=138,152,150,149,152,146,147,140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="83" upper_limit="94"/>
                    <measurement group_id="O2" value="89" lower_limit="83" upper_limit="93"/>
                    <measurement group_id="O3" value="78" lower_limit="71" upper_limit="84"/>
                    <measurement group_id="O4" value="18" lower_limit="12" upper_limit="25"/>
                    <measurement group_id="O5" value="83" lower_limit="76" upper_limit="89"/>
                    <measurement group_id="O6" value="88" lower_limit="82" upper_limit="93"/>
                    <measurement group_id="O7" value="24" lower_limit="18" upper_limit="32"/>
                    <measurement group_id="O8" value="90" lower_limit="84" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Bactericidal Titers, After Primary and Booster Vaccinations (Men B at 12 Months of Age)</title>
        <description>To assess the induction of immunological memory of three doses of meningococcal multi-component recombinant, adsorbed vaccine by comparing the serum bactericidal antibodies Geometric Mean Bactericidal Titers (GMTs) response in healthy toddlers administered the fourth dose at 12 months of age to the response in meningococcal B vaccine naive toddlers (Group VII) receiving the first dose of meningococcal multi-component recombinant, adsorbed vaccine at 12 months of age.</description>
        <time_frame>At 13 months</time_frame>
        <population>The analysis was done on the Per Protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>B+OMV (Group I)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation I) and routine vaccines at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenC (Group VII)</title>
            <description>Subjects received one dose of meningococcal C conjugate vaccine (Menjugate®; Men C) and routine vaccine at 2,3,4 months of age, one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation VII) and routine vaccine at 12 months of age, one dose of rMenB+OMV NZ and one dose of MenC at 13 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Bactericidal Titers, After Primary and Booster Vaccinations (Men B at 12 Months of Age)</title>
          <description>To assess the induction of immunological memory of three doses of meningococcal multi-component recombinant, adsorbed vaccine by comparing the serum bactericidal antibodies Geometric Mean Bactericidal Titers (GMTs) response in healthy toddlers administered the fourth dose at 12 months of age to the response in meningococcal B vaccine naive toddlers (Group VII) receiving the first dose of meningococcal multi-component recombinant, adsorbed vaccine at 12 months of age.</description>
          <population>The analysis was done on the Per Protocol population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>44/76-SL &gt; Booster (N=65,75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" lower_limit="95" upper_limit="150"/>
                    <measurement group_id="O2" value="12" lower_limit="10" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 &gt; Booster (N=73,69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1950" lower_limit="1573" upper_limit="2417"/>
                    <measurement group_id="O2" value="41" lower_limit="29" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 &gt; Booster</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="16" upper_limit="24"/>
                    <measurement group_id="O2" value="2.2" lower_limit="1.89" upper_limit="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA ≥1:5, First Dose of Meningococcal B Vaccine (One Month After Booster)</title>
        <description>To assess the immune response of first dose of meningococcal multi-component recombinant, adsorbed vaccine given at 12 months of age to toddlers who previously received three doses of MenC-CRM197 vaccine as infants (group VII).</description>
        <time_frame>1 month after booster</time_frame>
        <population>The analysis was done on the Per Protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenC (Group VII)</title>
            <description>Subjects received one dose of meningococcal C conjugate vaccine (Menjugate®; Men C) and routine vaccine at 2,3,4 months of age, one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation VII) and routine vaccine at 12 months of age, one dose of rMenB+OMV NZ and one dose of MenC at 13 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA ≥1:5, First Dose of Meningococcal B Vaccine (One Month After Booster)</title>
          <description>To assess the immune response of first dose of meningococcal multi-component recombinant, adsorbed vaccine given at 12 months of age to toddlers who previously received three doses of MenC-CRM197 vaccine as infants (group VII).</description>
          <population>The analysis was done on the Per Protocol population.</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>44/76-SL &gt; Booster (N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="74" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 &gt; Booster (N=69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="84" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 &gt; Booster</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="18" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Reactogenicity of Study Vaccines Within 7 Days After Second and Third Vaccination</title>
        <description>To assess if any of six different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (Group II to VI, Group VIII) reduced the incidence of fever ≥ 38.5ºC (rectal) occurring within 3 days (day 1-3) following second and third vaccination and 7 days (day 1-7) following each vaccination as compared to rMenB+OMV NZ (Group I).</description>
        <time_frame>Day 1 through day 7 after second and third vaccination.</time_frame>
        <population>As per safety dataset.</population>
        <group_list>
          <group group_id="O1">
            <title>B+OMV (Group I)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation I) and routine vaccines at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age..</description>
          </group>
          <group group_id="O2">
            <title>B+½ OMV (Group II)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation II) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B+1/4 OMV (Group III)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation III) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O4">
            <title>B (Group IV)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation IV) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O5">
            <title>½ (B+OMV) (Group V)</title>
            <description>Subjects in this group received one dose of meningococcal multi-component recombinant, adsorbed vaccine (formulation V)and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O6">
            <title>PH2 B+OMV (Group VI)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation VI) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age..</description>
          </group>
          <group group_id="O7">
            <title>MenC (Group VII)</title>
            <description>Subjects received one dose of meningococcal C conjugate vaccine (Menjugate®; Men C) and routine vaccine at 2,3,4 months of age, one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation VII) and routine vaccine at 12 months of age, one dose of rMenB+OMV NZ and one dose of MenC at 13 months of age.</description>
          </group>
          <group group_id="O8">
            <title>Par+B+OMV (Group VIII)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation I) with paracetamol and routine vaccines at 2,3,4,12 months of age and MenCCRM197 at 13 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Reactogenicity of Study Vaccines Within 7 Days After Second and Third Vaccination</title>
          <description>To assess if any of six different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (Group II to VI, Group VIII) reduced the incidence of fever ≥ 38.5ºC (rectal) occurring within 3 days (day 1-3) following second and third vaccination and 7 days (day 1-7) following each vaccination as compared to rMenB+OMV NZ (Group I).</description>
          <population>As per safety dataset.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="186"/>
                <count group_id="O4" value="184"/>
                <count group_id="O5" value="182"/>
                <count group_id="O6" value="180"/>
                <count group_id="O7" value="177"/>
                <count group_id="O8" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Second Vaccination (day1-3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="76"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="74"/>
                    <measurement group_id="O6" value="89"/>
                    <measurement group_id="O7" value="30"/>
                    <measurement group_id="O8" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd vac d 1-3(N=181,179,185,183,181,180,177,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="40"/>
                    <measurement group_id="O6" value="53"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Vaccination (day1-7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="60"/>
                    <measurement group_id="O6" value="76"/>
                    <measurement group_id="O7" value="22"/>
                    <measurement group_id="O8" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second Vaccination (day 1-7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="74"/>
                    <measurement group_id="O6" value="90"/>
                    <measurement group_id="O7" value="30"/>
                    <measurement group_id="O8" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd vac d 1-7(N=181,179,185,183,181,180,177,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="42"/>
                    <measurement group_id="O6" value="54"/>
                    <measurement group_id="O7" value="14"/>
                    <measurement group_id="O8" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Booster d 1-7(N=155,162,169,168,168,165,164,159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="43"/>
                    <measurement group_id="O5" value="78"/>
                    <measurement group_id="O6" value="68"/>
                    <measurement group_id="O7" value="84"/>
                    <measurement group_id="O8" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local Reactions Within 7 Days (Day 1-7) After Each Vaccination</title>
        <description>To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting solicited local reactions within 7 days (day 1-7) after each vaccination.</description>
        <time_frame>Day 1 through day 7 after each vaccination.</time_frame>
        <population>The analysis was performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>B+OMV (Group I)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation I) and routine vaccines at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B+½ OMV (Group II)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation II) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B+1/4 OMV (Group III)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation III) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O4">
            <title>B (Group IV)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation IV) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O5">
            <title>½ (B+OMV) (Group V)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation V) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O6">
            <title>PH2 B+OMV (Group VI)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation VI) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O7">
            <title>MenC (Group VII)</title>
            <description>Subjects received one dose of meningococcal C conjugate vaccine (Menjugate®; Men C) and routine vaccine at 2,3,4 months of age, one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation VII) and routine vaccine at 12 months of age, one dose of rMenB+OMV NZ and one dose of MenC at 13 months of age.</description>
          </group>
          <group group_id="O8">
            <title>Par+B+OMV (Group VIII)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation I) with paracetamol and routine vaccines at 2,3,4,12 months of age and MenCCRM197 at 13 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local Reactions Within 7 Days (Day 1-7) After Each Vaccination</title>
          <description>To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting solicited local reactions within 7 days (day 1-7) after each vaccination.</description>
          <population>The analysis was performed on the safety population.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="186"/>
                <count group_id="O4" value="184"/>
                <count group_id="O5" value="182"/>
                <count group_id="O6" value="180"/>
                <count group_id="O7" value="177"/>
                <count group_id="O8" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Local (First Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="155"/>
                    <measurement group_id="O3" value="153"/>
                    <measurement group_id="O4" value="123"/>
                    <measurement group_id="O5" value="141"/>
                    <measurement group_id="O6" value="157"/>
                    <measurement group_id="O7" value="127"/>
                    <measurement group_id="O8" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Tenderness (First Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="116"/>
                    <measurement group_id="O3" value="111"/>
                    <measurement group_id="O4" value="54"/>
                    <measurement group_id="O5" value="97"/>
                    <measurement group_id="O6" value="121"/>
                    <measurement group_id="O7" value="48"/>
                    <measurement group_id="O8" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Erythema (First Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="53"/>
                    <measurement group_id="O5" value="77"/>
                    <measurement group_id="O6" value="106"/>
                    <measurement group_id="O7" value="45"/>
                    <measurement group_id="O8" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Induration (First Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="85"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="86"/>
                    <measurement group_id="O6" value="84"/>
                    <measurement group_id="O7" value="25"/>
                    <measurement group_id="O8" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Swelling (First Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="48"/>
                    <measurement group_id="O6" value="60"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Local (Second Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="156"/>
                    <measurement group_id="O3" value="155"/>
                    <measurement group_id="O4" value="126"/>
                    <measurement group_id="O5" value="132"/>
                    <measurement group_id="O6" value="156"/>
                    <measurement group_id="O7" value="118"/>
                    <measurement group_id="O8" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Tenderness (Second Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="116"/>
                    <measurement group_id="O3" value="97"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="88"/>
                    <measurement group_id="O6" value="116"/>
                    <measurement group_id="O7" value="47"/>
                    <measurement group_id="O8" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Erythema (Second Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="114"/>
                    <measurement group_id="O3" value="114"/>
                    <measurement group_id="O4" value="71"/>
                    <measurement group_id="O5" value="90"/>
                    <measurement group_id="O6" value="104"/>
                    <measurement group_id="O7" value="44"/>
                    <measurement group_id="O8" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Induration (Second Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="105"/>
                    <measurement group_id="O3" value="97"/>
                    <measurement group_id="O4" value="63"/>
                    <measurement group_id="O5" value="83"/>
                    <measurement group_id="O6" value="94"/>
                    <measurement group_id="O7" value="38"/>
                    <measurement group_id="O8" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Swelling (Second Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="50"/>
                    <measurement group_id="O6" value="58"/>
                    <measurement group_id="O7" value="21"/>
                    <measurement group_id="O8" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Local (3rd N=181,179,185,183,181,180,177,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="147"/>
                    <measurement group_id="O3" value="141"/>
                    <measurement group_id="O4" value="122"/>
                    <measurement group_id="O5" value="130"/>
                    <measurement group_id="O6" value="152"/>
                    <measurement group_id="O7" value="113"/>
                    <measurement group_id="O8" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Tenderness (Third Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="77"/>
                    <measurement group_id="O6" value="111"/>
                    <measurement group_id="O7" value="42"/>
                    <measurement group_id="O8" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Erythema (Third Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="112"/>
                    <measurement group_id="O4" value="72"/>
                    <measurement group_id="O5" value="94"/>
                    <measurement group_id="O6" value="101"/>
                    <measurement group_id="O7" value="63"/>
                    <measurement group_id="O8" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Induration (Third Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="62"/>
                    <measurement group_id="O5" value="79"/>
                    <measurement group_id="O6" value="89"/>
                    <measurement group_id="O7" value="55"/>
                    <measurement group_id="O8" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Swelling (Third Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="45"/>
                    <measurement group_id="O6" value="58"/>
                    <measurement group_id="O7" value="29"/>
                    <measurement group_id="O8" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Local BoostN=155,162,169,168,168,165,162,159</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="132"/>
                    <measurement group_id="O3" value="149"/>
                    <measurement group_id="O4" value="113"/>
                    <measurement group_id="O5" value="127"/>
                    <measurement group_id="O6" value="130"/>
                    <measurement group_id="O7" value="133"/>
                    <measurement group_id="O8" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Tenderness (Booster Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="120"/>
                    <measurement group_id="O4" value="77"/>
                    <measurement group_id="O5" value="106"/>
                    <measurement group_id="O6" value="112"/>
                    <measurement group_id="O7" value="108"/>
                    <measurement group_id="O8" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Erythema (Booster Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="116"/>
                    <measurement group_id="O4" value="67"/>
                    <measurement group_id="O5" value="80"/>
                    <measurement group_id="O6" value="85"/>
                    <measurement group_id="O7" value="93"/>
                    <measurement group_id="O8" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Induration (Booster Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="56"/>
                    <measurement group_id="O5" value="66"/>
                    <measurement group_id="O6" value="73"/>
                    <measurement group_id="O7" value="62"/>
                    <measurement group_id="O8" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Swelling (Booster Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="47"/>
                    <measurement group_id="O6" value="52"/>
                    <measurement group_id="O7" value="39"/>
                    <measurement group_id="O8" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Fever ≥ 38.5 °C (Rectal Temperature) Within 3 Days (Day 1-3) After First Vaccination</title>
        <description>To assess if any of six different formulations of vaccine groups (Group II to Group VI, Group VIII) reduced the incidence of fever &gt;=38.5C (rectal) occurring within three days (day 1-day3) following first vaccination. The analysis was done on the Safety Population.</description>
        <time_frame>Day 1 to day 3 after first vaccination.</time_frame>
        <population>The analysis was done on the Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>B+OMV (Group I)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation I) and routine vaccines at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B+½ OMV (Group II)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation II) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B+1/4 OMV (Group III)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation III) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O4">
            <title>B (Group IV)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation IV) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O5">
            <title>½ (B+OMV) (Group V)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation V) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O6">
            <title>PH2 B+OMV (Group VI)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation VI) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O7">
            <title>MenC (Group VII)</title>
            <description>Subjects received one dose of meningococcal C conjugate vaccine (Menjugate®; Men C) and routine vaccine at 2,3,4 months of age, one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation VII) and routine vaccine at 12 months of age, one dose of rMenB+OMV NZ and one dose of MenC at 13 months of age.</description>
          </group>
          <group group_id="O8">
            <title>Par+B+OMV (Group VIII)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation I) with paracetamol and routine vaccines at 2,3,4,12 months of age and MenCCRM197 at 13 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Fever ≥ 38.5 °C (Rectal Temperature) Within 3 Days (Day 1-3) After First Vaccination</title>
          <description>To assess if any of six different formulations of vaccine groups (Group II to Group VI, Group VIII) reduced the incidence of fever &gt;=38.5C (rectal) occurring within three days (day 1-day3) following first vaccination. The analysis was done on the Safety Population.</description>
          <population>The analysis was done on the Safety Population.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="186"/>
                <count group_id="O4" value="184"/>
                <count group_id="O5" value="182"/>
                <count group_id="O6" value="180"/>
                <count group_id="O7" value="177"/>
                <count group_id="O8" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="60"/>
                    <measurement group_id="O6" value="76"/>
                    <measurement group_id="O7" value="21"/>
                    <measurement group_id="O8" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Systemic Reactions Within 7 Days (Day 1-7) After Each Vaccination</title>
        <description>To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting solicited systemic reactions within 7 days (day 1-7) after each vaccination.</description>
        <time_frame>Day 1 through day 7 after each vaccination.</time_frame>
        <population>The analysis was performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>B+OMV (Group I)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation I) and routine vaccines at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B+½ OMV (Group II)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation II) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B+1/4 OMV (Group III)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation III) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O4">
            <title>B (Group IV)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation IV) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O5">
            <title>½ (B+OMV) (Group V)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation V) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O6">
            <title>PH2 B+OMV (Group VI)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation VI) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O7">
            <title>MenC (Group VII)</title>
            <description>Subjects received one dose of meningococcal C conjugate vaccine (Menjugate®; Men C) and routine vaccine at 2,3,4 months of age, one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation VII) and routine vaccine at 12 months of age, one dose of rMenB+OMV NZ and one dose of MenC at 13 months of age.</description>
          </group>
          <group group_id="O8">
            <title>Par+B+OMV (Group VIII)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation I) with paracetamol and routine vaccines at 2,3,4,12 months of age and MenCCRM197 at 13 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Systemic Reactions Within 7 Days (Day 1-7) After Each Vaccination</title>
          <description>To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting solicited systemic reactions within 7 days (day 1-7) after each vaccination.</description>
          <population>The analysis was performed on the safety population.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="186"/>
                <count group_id="O4" value="184"/>
                <count group_id="O5" value="182"/>
                <count group_id="O6" value="180"/>
                <count group_id="O7" value="177"/>
                <count group_id="O8" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Systemic (First Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="173"/>
                    <measurement group_id="O3" value="175"/>
                    <measurement group_id="O4" value="152"/>
                    <measurement group_id="O5" value="162"/>
                    <measurement group_id="O6" value="171"/>
                    <measurement group_id="O7" value="136"/>
                    <measurement group_id="O8" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Eat. Habits (First Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="84"/>
                    <measurement group_id="O4" value="52"/>
                    <measurement group_id="O5" value="84"/>
                    <measurement group_id="O6" value="90"/>
                    <measurement group_id="O7" value="41"/>
                    <measurement group_id="O8" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (First Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="131"/>
                    <measurement group_id="O3" value="119"/>
                    <measurement group_id="O4" value="96"/>
                    <measurement group_id="O5" value="117"/>
                    <measurement group_id="O6" value="119"/>
                    <measurement group_id="O7" value="92"/>
                    <measurement group_id="O8" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (First Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="26"/>
                    <measurement group_id="O7" value="17"/>
                    <measurement group_id="O8" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (First Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="41"/>
                    <measurement group_id="O6" value="49"/>
                    <measurement group_id="O7" value="45"/>
                    <measurement group_id="O8" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (First Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="124"/>
                    <measurement group_id="O3" value="128"/>
                    <measurement group_id="O4" value="99"/>
                    <measurement group_id="O5" value="131"/>
                    <measurement group_id="O6" value="131"/>
                    <measurement group_id="O7" value="79"/>
                    <measurement group_id="O8" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unus Crying (First Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="105"/>
                    <measurement group_id="O4" value="61"/>
                    <measurement group_id="O5" value="96"/>
                    <measurement group_id="O6" value="108"/>
                    <measurement group_id="O7" value="63"/>
                    <measurement group_id="O8" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (First Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ( ≥ 38.5°C ) (First Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="60"/>
                    <measurement group_id="O6" value="76"/>
                    <measurement group_id="O7" value="22"/>
                    <measurement group_id="O8" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyr. Med. Used (First Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="37"/>
                    <measurement group_id="O5" value="74"/>
                    <measurement group_id="O6" value="95"/>
                    <measurement group_id="O7" value="32"/>
                    <measurement group_id="O8" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic (Second Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="158"/>
                    <measurement group_id="O3" value="166"/>
                    <measurement group_id="O4" value="144"/>
                    <measurement group_id="O5" value="156"/>
                    <measurement group_id="O6" value="158"/>
                    <measurement group_id="O7" value="126"/>
                    <measurement group_id="O8" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Eat. Habits (Second Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="53"/>
                    <measurement group_id="O5" value="60"/>
                    <measurement group_id="O6" value="80"/>
                    <measurement group_id="O7" value="33"/>
                    <measurement group_id="O8" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (Second Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="102"/>
                    <measurement group_id="O4" value="85"/>
                    <measurement group_id="O5" value="92"/>
                    <measurement group_id="O6" value="109"/>
                    <measurement group_id="O7" value="75"/>
                    <measurement group_id="O8" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (Second Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="14"/>
                    <measurement group_id="O8" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (Second Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="39"/>
                    <measurement group_id="O6" value="47"/>
                    <measurement group_id="O7" value="39"/>
                    <measurement group_id="O8" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (Second Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="121"/>
                    <measurement group_id="O3" value="124"/>
                    <measurement group_id="O4" value="94"/>
                    <measurement group_id="O5" value="117"/>
                    <measurement group_id="O6" value="126"/>
                    <measurement group_id="O7" value="82"/>
                    <measurement group_id="O8" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unus Crying (Second Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="84"/>
                    <measurement group_id="O4" value="70"/>
                    <measurement group_id="O5" value="83"/>
                    <measurement group_id="O6" value="99"/>
                    <measurement group_id="O7" value="45"/>
                    <measurement group_id="O8" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (Second Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ( ≥ 38.5°C ) (Second Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="74"/>
                    <measurement group_id="O6" value="90"/>
                    <measurement group_id="O7" value="30"/>
                    <measurement group_id="O8" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyr. Med. Used (Second Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="83"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="79"/>
                    <measurement group_id="O6" value="105"/>
                    <measurement group_id="O7" value="39"/>
                    <measurement group_id="O8" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Syst (3rdN=181,179,185,182,181,180,177,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="131"/>
                    <measurement group_id="O3" value="132"/>
                    <measurement group_id="O4" value="122"/>
                    <measurement group_id="O5" value="141"/>
                    <measurement group_id="O6" value="151"/>
                    <measurement group_id="O7" value="106"/>
                    <measurement group_id="O8" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Eat. Habits (Third Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="37"/>
                    <measurement group_id="O5" value="45"/>
                    <measurement group_id="O6" value="60"/>
                    <measurement group_id="O7" value="22"/>
                    <measurement group_id="O8" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (Third Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="82"/>
                    <measurement group_id="O4" value="64"/>
                    <measurement group_id="O5" value="77"/>
                    <measurement group_id="O6" value="79"/>
                    <measurement group_id="O7" value="52"/>
                    <measurement group_id="O8" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (Third Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (Third Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="40"/>
                    <measurement group_id="O7" value="19"/>
                    <measurement group_id="O8" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (Third Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="74"/>
                    <measurement group_id="O5" value="104"/>
                    <measurement group_id="O6" value="115"/>
                    <measurement group_id="O7" value="76"/>
                    <measurement group_id="O8" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unus Crying (Third Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="69"/>
                    <measurement group_id="O6" value="100"/>
                    <measurement group_id="O7" value="38"/>
                    <measurement group_id="O8" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (Third Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ( ≥ 38.5°C ) (Third Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="42"/>
                    <measurement group_id="O6" value="54"/>
                    <measurement group_id="O7" value="14"/>
                    <measurement group_id="O8" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyr. Med. Used (Third Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="49"/>
                    <measurement group_id="O6" value="63"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Syst(BoosterN=155,162,169,169,168,165,164,159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="144"/>
                    <measurement group_id="O3" value="139"/>
                    <measurement group_id="O4" value="118"/>
                    <measurement group_id="O5" value="141"/>
                    <measurement group_id="O6" value="142"/>
                    <measurement group_id="O7" value="142"/>
                    <measurement group_id="O8" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Eat. Habits (Booster Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="79"/>
                    <measurement group_id="O4" value="52"/>
                    <measurement group_id="O5" value="70"/>
                    <measurement group_id="O6" value="80"/>
                    <measurement group_id="O7" value="59"/>
                    <measurement group_id="O8" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (Booster Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="90"/>
                    <measurement group_id="O4" value="63"/>
                    <measurement group_id="O5" value="86"/>
                    <measurement group_id="O6" value="88"/>
                    <measurement group_id="O7" value="85"/>
                    <measurement group_id="O8" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (Booster Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (Booster Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="43"/>
                    <measurement group_id="O5" value="32"/>
                    <measurement group_id="O6" value="30"/>
                    <measurement group_id="O7" value="26"/>
                    <measurement group_id="O8" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (Booster Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="112"/>
                    <measurement group_id="O4" value="86"/>
                    <measurement group_id="O5" value="116"/>
                    <measurement group_id="O6" value="115"/>
                    <measurement group_id="O7" value="117"/>
                    <measurement group_id="O8" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unus Crying (Booster Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="71"/>
                    <measurement group_id="O6" value="82"/>
                    <measurement group_id="O7" value="73"/>
                    <measurement group_id="O8" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (Booster Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ( ≥ 38.5°C ) (Booster Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="43"/>
                    <measurement group_id="O5" value="78"/>
                    <measurement group_id="O6" value="68"/>
                    <measurement group_id="O7" value="84"/>
                    <measurement group_id="O8" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyr. Med. Used (Booster Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="83"/>
                    <measurement group_id="O4" value="42"/>
                    <measurement group_id="O5" value="75"/>
                    <measurement group_id="O6" value="80"/>
                    <measurement group_id="O7" value="92"/>
                    <measurement group_id="O8" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Unsolicited Adverse Events Within 7 Days (Day 1-7) After Each Vaccination</title>
        <description>To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting unsolicited Adverse Events (AEs), serious adverse events (SAEs), medically attended AEs, AEs leading to premature withdrawal (throughout the study period) within 7 days (day 1-7) after each vaccination.</description>
        <time_frame>Day 1 through day 7 after each vaccination.</time_frame>
        <population>The analysis was performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>B+OMV (Group I)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation I) and routine vaccines at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B+½ OMV (Group II)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation II) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B+1/4 OMV (Group III)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation III) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O4">
            <title>B (Group IV)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation IV) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O5">
            <title>½ (B+OMV) (Group V)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation V) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O6">
            <title>PH2 B+OMV (Group VI)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation VI) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O7">
            <title>MenC (Group VII)</title>
            <description>Subjects received one dose of meningococcal C conjugate vaccine (Menjugate®; Men C) and routine vaccine at 2,3,4 months of age, one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation VII) and routine vaccine at 12 months of age, one dose of rMenB+OMV NZ and one dose of MenC at 13 months of age.</description>
          </group>
          <group group_id="O8">
            <title>Par+B+OMV (Group VIII)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation I) with paracetamol and routine vaccines at 2,3,4,12 months of age and MenCCRM197 at 13 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Unsolicited Adverse Events Within 7 Days (Day 1-7) After Each Vaccination</title>
          <description>To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting unsolicited Adverse Events (AEs), serious adverse events (SAEs), medically attended AEs, AEs leading to premature withdrawal (throughout the study period) within 7 days (day 1-7) after each vaccination.</description>
          <population>The analysis was performed on the safety population.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="184"/>
                <count group_id="O3" value="189"/>
                <count group_id="O4" value="187"/>
                <count group_id="O5" value="187"/>
                <count group_id="O6" value="185"/>
                <count group_id="O7" value="184"/>
                <count group_id="O8" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE (Day 1 to 7) (First Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="39"/>
                    <measurement group_id="O7" value="27"/>
                    <measurement group_id="O8" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least Possibly related AE (First Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="27"/>
                    <measurement group_id="O6" value="34"/>
                    <measurement group_id="O7" value="22"/>
                    <measurement group_id="O8" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE (First Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE D1-7 2nd N=182,181,186,184,183,180,178,180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="47"/>
                    <measurement group_id="O7" value="28"/>
                    <measurement group_id="O8" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least Possibly related AE (Second Vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="41"/>
                    <measurement group_id="O7" value="26"/>
                    <measurement group_id="O8" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE (Second Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE D1-7 3rd N=182,181,186,184,182,180,177,179</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="45"/>
                    <measurement group_id="O7" value="35"/>
                    <measurement group_id="O8" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least Possibly related AE (Third Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="37"/>
                    <measurement group_id="O7" value="29"/>
                    <measurement group_id="O8" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE (Third Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE D 1-7Boos N=155,163,169,169,168,165,165,161</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="56"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="30"/>
                    <measurement group_id="O7" value="37"/>
                    <measurement group_id="O8" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least Possibly related AE (Booster Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="26"/>
                    <measurement group_id="O7" value="30"/>
                    <measurement group_id="O8" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE (Booster Vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Severe Adverse Events and Adverse Events Necessitating a Medical Office or Emergency Room (ER) Visit and/or Resulting in Premature Withdrawal of the Subject From the Study, Throughout the Study Period.</title>
        <description>To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting Severe Adverse Events (SAEs) and Adverse Events (AEs) necessitating a medical office or Emergency Room (ER) visit and/or resulting in premature withdrawal of the subject from the study, throughout the study period.</description>
        <time_frame>Overall study period.</time_frame>
        <population>The analysis was performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>B+OMV (Group I)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation I) and routine vaccines at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B+½ OMV (Group II)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation II) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B+1/4 OMV (Group III)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation III) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O4">
            <title>B (Group IV)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation IV) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O5">
            <title>½ (B+OMV) (Group V)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation V) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O6">
            <title>PH2 B+OMV (Group VI)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant adsorbed vaccine (formulation VI) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
          </group>
          <group group_id="O7">
            <title>MenC (Group VII)</title>
            <description>Subjects received one dose of meningococcal C conjugate vaccine (Menjugate®; Men C) and routine vaccine at 2,3,4 months of age, one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation VII) and routine vaccine at 12 months of age, one dose of rMenB+OMV NZ and one dose of MenC at 13 months of age.</description>
          </group>
          <group group_id="O8">
            <title>Par+B+OMV (Group VIII)</title>
            <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation I) with paracetamol and routine vaccines at 2,3,4,12 months of age and MenCCRM197 at 13 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Severe Adverse Events and Adverse Events Necessitating a Medical Office or Emergency Room (ER) Visit and/or Resulting in Premature Withdrawal of the Subject From the Study, Throughout the Study Period.</title>
          <description>To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting Severe Adverse Events (SAEs) and Adverse Events (AEs) necessitating a medical office or Emergency Room (ER) visit and/or resulting in premature withdrawal of the subject from the study, throughout the study period.</description>
          <population>The analysis was performed on the safety population.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="184"/>
                <count group_id="O3" value="189"/>
                <count group_id="O4" value="187"/>
                <count group_id="O5" value="187"/>
                <count group_id="O6" value="185"/>
                <count group_id="O7" value="184"/>
                <count group_id="O8" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AE Leading to Premature Withdrawal-Primary Vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Emergent SAEs - Primary Vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="16"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tr E SAE Boost (N=155,163,169,169,168,165,165,161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Local and Systemic Reactions Within 7 Days (Day 1-7) After Second rMenB+OMV NZ Vaccination in MenC Group</title>
        <description>To assess the safety and tolerability of two doses of rMenB+OMV NZ vaccine (Group VII) given at 12 and 13 months of age to toddlers who previously received three doses of Menjugate as infants.</description>
        <time_frame>Day 1 through day 7 at 13 months age.</time_frame>
        <population>The analysis was performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenC (Group VII)</title>
            <description>Subjects received one dose of meningococcal C conjugate vaccine (Menjugate®; Men C) and routine vaccine at 2,3,4 months of age, one dose of meningococcal B recombinant (rMenB+OMV NZ) adsorbed vaccine (formulation VII) and routine vaccine at 12 months of age, one dose of rMenB+OMV NZ and one dose of MenC at 13 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Local and Systemic Reactions Within 7 Days (Day 1-7) After Second rMenB+OMV NZ Vaccination in MenC Group</title>
          <description>To assess the safety and tolerability of two doses of rMenB+OMV NZ vaccine (Group VII) given at 12 and 13 months of age to toddlers who previously received three doses of Menjugate as infants.</description>
          <population>The analysis was performed on the safety population.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection Site Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Eat. Habits (N=155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unus Crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ( ≥ 38.5°C ) (N=158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyr. Med. Used (N=157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All solicited AEs and unsolicited AEs were collected from Day 1 to Day 7; serious adverse events (SAEs), medically attended AEs, AEs leading to premature withdrawal were collected during the overall study period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>B+OMV (Group I)</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation I) and routine vaccines at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.
Group defined to be applicable Prior to Booster Phase for AEs reporting.</description>
        </group>
        <group group_id="E2">
          <title>B+½ OMV (Group II)</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation II) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.
Group defined to be applicable Prior to Booster Phase for AEs reporting.</description>
        </group>
        <group group_id="E3">
          <title>B+1/4 OMV (Group III)</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation III) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.
Group defined to be applicable Prior to Booster Phase for AEs reporting.</description>
        </group>
        <group group_id="E4">
          <title>B (Group IV)</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation IV) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.
Group defined to be applicable Prior to Booster Phase for AEs reporting..</description>
        </group>
        <group group_id="E5">
          <title>½ (B+OMV) (Group V)</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation V) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.
Group defined to be applicable Prior to Booster Phase for AEs reporting.</description>
        </group>
        <group group_id="E6">
          <title>PH2 B+OMV (Group VI)</title>
          <description>SubjSubjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation VI) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.
Group defined to be applicable Prior to Booster Phase for AEs reporting.</description>
        </group>
        <group group_id="E7">
          <title>MenC (Group VII)</title>
          <description>Subjects received one dose of meningococcal C conjugate vaccine (Menjugate®; Men C) and routine vaccine at 2,3,4 months of age and one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation VII) and routine vaccine at 12 months of age. One dose of MenC at 13 months of age.
Group defined to be applicable Prior to Booster Phase for AEs reporting.</description>
        </group>
        <group group_id="E8">
          <title>Par+B+OMV (Group VIII)</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation I) with paracetamol and routine vaccines at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age. Group defined to be applicable Prior to Booster Phase for AEs reporting.</description>
        </group>
        <group group_id="E9">
          <title>B+OMV (Group I) Booster Phase</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation I) and routine vaccines at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.</description>
        </group>
        <group group_id="E10">
          <title>B+½ OMV (Group II) Booster Phase</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine(formulation II) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.
Group defined to include Booster Phase.</description>
        </group>
        <group group_id="E11">
          <title>B+1/4 OMV (Group III) Booster Phase</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation III) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.
Group defined to include Booster Phase.</description>
        </group>
        <group group_id="E12">
          <title>B (Group IV) Booster Phase</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation IV) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.
Group defined to include Booster Phase.</description>
        </group>
        <group group_id="E13">
          <title>½ (B+OMV) (Group V) Booster Phase</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation V) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.
Group defined to include Booster Phase.</description>
        </group>
        <group group_id="E14">
          <title>PH2 B+OMV (Group VI) Booster Phase</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation VI) and routine vaccine at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age.
Group defined to include Booster Phase.</description>
        </group>
        <group group_id="E15">
          <title>MenC (Group VII) Booster Phase</title>
          <description>Subjects received one dose of meningococcal C conjugate vaccine (Menjugate®; Men C) and routine vaccine at 2,3,4 months of age and one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation VII) and routine vaccine at 12 months of age. One dose of MenC at 13 months of age.
Group defined to include Booster Phase.</description>
        </group>
        <group group_id="E16">
          <title>Par+B+OMV (Group VIII) Booster Phase</title>
          <description>Subjects in this group received one dose of meningococcal B recombinant (rMenB) adsorbed vaccine (formulation I) with paracetamol and routine vaccines at 2,3,4,12 months of age and MenC-CRM197 at 13 months of age. Group defined to include Booster Phase.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="12" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="15" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="9" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="9" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="14" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital megacolon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cryptorchism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Enterocolitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Corona virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Bullous impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Viral myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bone fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Foreign body aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Accidental exposure to product</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Acoustic Stimulation Tests</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Ketosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Weight gain poor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Fibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Myoclonic epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>VIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Adenoidal hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cleft palate repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="181" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="183" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="186" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="183" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="180" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="180" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="175" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="175" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="151" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="159" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="162" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="152" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="154" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="156" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="155" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="150" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="67" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="80" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="81" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="74" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="73" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="31" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="37" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="39" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="47" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="34" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="31" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="40" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="34" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="43" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="34" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="46" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="13" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="10" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="15" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="20" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="135" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="137" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="99" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="125" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="141" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="87" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="112" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="74" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="64" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="69" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="46" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="71" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="82" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="85" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="50" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="150" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="155" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="132" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="131" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="150" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="119" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="132" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="97" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="107" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="120" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="83" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="89" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="96" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="110" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="88" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="139" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="141" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="126" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="130" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="130" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="122" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="126" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="81" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="90" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="105" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="71" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="76" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="81" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="97" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="70" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="150" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="157" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="139" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="101" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="131" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="152" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="105" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="119" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="121" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="110" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="126" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="92" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="111" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="116" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="125" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="97" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="122" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="71" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="114" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="126" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="62" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="78" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="86" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="94" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="70" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="49" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="85" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="72" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="92" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="59" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="103" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="80" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="88" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="100" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="75" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="77" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="57" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="63" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="76" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="46" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="53" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="57" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="65" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="50" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="43" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="34" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="35" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="25" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="18" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="25" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="28" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="28" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="19" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="35" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="17" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="13" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="10" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="9" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="11" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="7" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="10" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="12" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="15" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="9" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="7" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="15" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="18" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="14" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="15" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="14" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="7" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="16" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="13" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="14" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="22" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="15" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="16" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="15" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="10" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="6" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="9" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="9" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="8" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="21" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="14" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="16" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="18" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="9" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="12" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="11" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="149" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="146" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="131" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="142" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="143" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="113" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="134" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="76" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="90" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="90" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="63" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="86" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="88" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="100" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="80" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Eating disorder</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="104" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="84" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="112" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="119" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="63" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="93" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="74" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="77" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="79" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="52" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="70" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="80" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="72" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="66" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="159" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="155" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="139" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="151" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="153" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="121" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="137" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="116" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="111" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="112" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="86" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="116" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="115" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="126" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="96" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="12" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="7" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="187"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="185"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="184"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="183"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="163"/>
                <counts group_id="E11" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E13" subjects_affected="9" subjects_at_risk="168"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E15" subjects_affected="12" subjects_at_risk="165"/>
                <counts group_id="E16" subjects_affected="7" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Novartis Vaccines</name_or_title>
      <organization>Novartis Vaccines</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

